These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16630956)

  • 21. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
    Worm M
    Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiallergen immunotherapy for allergic rhinitis and asthma.
    Nelson HS
    J Allergy Clin Immunol; 2009 Apr; 123(4):763-9. PubMed ID: 19217653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.
    Savolainen J; Jacobsen L; Valovirta E
    Allergy; 2006 Oct; 61(10):1184-90. PubMed ID: 16942566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis.
    Ciprandi G; Contini P; Pistorio A; Murdaca G; Puppo F
    Int Immunopharmacol; 2009 Feb; 9(2):253-7. PubMed ID: 19100344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sublingual immunotherapy: from safety to mechanism of action.
    Marcucci F; Sensi L; Allocca G; Chiarello F; Palleri P; Ugolini E; Di Rienzo A; Castellani S; Incorvaia C; Di Cara G; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007 Mar; 39(3):101-3. PubMed ID: 17465282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States.
    Greenberger PA; Ballow M; Casale TB; Platts-Mills TA; Sampson HA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1466-8. PubMed ID: 17936891
    [No Abstract]   [Full Text] [Related]  

  • 28. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
    Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
    J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does sublingual immunotherapy work?
    Frew AJ
    J Allergy Clin Immunol; 2007 Sep; 120(3):533-6. PubMed ID: 17765753
    [No Abstract]   [Full Text] [Related]  

  • 30. Allergen-specific sublingual immunotherapy: less mystic, more scientific.
    Bieber T
    Allergy; 2006 Feb; 61(2):149-50. PubMed ID: 16409189
    [No Abstract]   [Full Text] [Related]  

  • 31. High-dose sublingual immunotherapy: too much of the good?
    Reider N
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):125. PubMed ID: 16937740
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
    Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
    Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoid sublingual immunotherapy.
    Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
    Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Instead of hyposensitization by injection. Dissolving immunotherapy under the tongue?].
    Klein F
    MMW Fortschr Med; 2007 Jan; 149(3):16. PubMed ID: 17632861
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality of life outcomes with sublingual immunotherapy.
    Wise SK; Woody J; Koepp S; Schlosser RJ
    Am J Otolaryngol; 2009; 30(5):305-11. PubMed ID: 19720247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Compliance analysis of sublingual immunotherapy and countermeasures].
    Chen J; Kong W; Xiang J; Lu Z; Zhou Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Mar; 24(5):203-6. PubMed ID: 20464985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on sublingual immunotherapy treatment regimes.
    Spangfort MD
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):244. PubMed ID: 17124783
    [No Abstract]   [Full Text] [Related]  

  • 38. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
    Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
    Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature.
    Leatherman BD; Owen S; Parker M; Chadwick S; Fornadley JA; Colson D; Fass P
    Otolaryngol Head Neck Surg; 2007 Mar; 136(3 Suppl):S1-20. PubMed ID: 17321336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sublingual vaccines based on wild-type recombinant allergens.
    Van Overtvelt L; Razafindratsita A; St-Lu N; Didierlaurent A; Batard T; Lombardi V; Martin E; Moingeon P
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.